Industry leaders from Cytiva and Merck KGaA highlight the emergence of Bioprocess 5.0, a new era combining artificial intelligence, advanced automation, and sustainability to enhance biologics and gene therapy manufacturing. This paradigm shift introduces in-line real-time monitoring, digital twins for risk-free scenario testing, and interoperable platforms to reduce batch failures and accelerate development. Enhanced process control and adaptive data-driven decisions promise to improve efficiency and environmental impact across biomanufacturing.